PD-L1 suppresses the immune response by interacting with Programmed cell death 1 (PD-1) (CD279) in T cells, thus inhibiting their activation and allowing cancer cells to evade immune surveillance [1,2]. This evidence concerns the gene PDCD1 and cancer.